Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof(Kaiser Permanente), John M. McLaughlin(Pfizer (United States)), Srinivas Rao Valluri(Pfizer (United States)), Timothy B. Frankland(Kaiser Permanente), Vennis Hong(Kaiser Permanente), Oluwaseye Ayoola Ogun(Kaiser Permanente), Jeff Slezak(Kaiser Permanente), Kaije Pan(Pfizer (United States)), Omesh N. Ranasinghe(Kaiser Permanente), Luis Jódar(Pfizer (United States)), Sharon Gray(Pfizer (United States)), Heidi Fischer(Kaiser Permanente), Bradley K. Ackerson, Joann M. Zamparo(Pfizer (United States)), Frederick J. Angulo(Pfizer (United States))

The Lancet

October 1, 2021

10.1016/s0140-6736(21)02183-8

Cited by 1,277

Related Papers

Foodborne Illness Acquired in the United States—Major Pathogens

|Emerging infectious diseases|2010|7.6k

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

|The Lancet|2021|1.7k

Attribution of Foodborne Illnesses, Hospitalizations, and Deaths to Food Commodities by using Outbreak Data, United States, 1998–2008

|Emerging infectious diseases|2013|1.1k

Foodborne Illness Acquired in the United States—Major Pathogens

|Emerging infectious diseases|2011|623

Bacterial Contamination of Animal Feed and Its Relationship to Human Foodborne Illness

|Clinical Infectious Diseases|2002|300